BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 2143637)

  • 1. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.
    Jenike MA; Hyman S; Baer L; Holland A; Minichiello WE; Buttolph L; Summergrad P; Seymour R; Ricciardi J
    Am J Psychiatry; 1990 Sep; 147(9):1209-15. PubMed ID: 2143637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo.
    Jenike MA; Baer L; Summergrad P; Minichiello WE; Holland A; Seymour R
    Am J Psychiatry; 1990 Jul; 147(7):923-8. PubMed ID: 2192564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
    Piccinelli M; Pini S; Bellantuono C; Wilkinson G
    Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
    Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Serlin RC
    Arch Gen Psychiatry; 1995 Jan; 52(1):53-60. PubMed ID: 7811162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvoxamine treatment of obsessive-compulsive disorder.
    Perse TL; Greist JH; Jefferson JW; Rosenfeld R; Dar R
    Am J Psychiatry; 1987 Dec; 144(12):1543-8. PubMed ID: 3120604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.
    Goodman WK; Price LH; Rasmussen SA; Delgado PL; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1989 Jan; 46(1):36-44. PubMed ID: 2491940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
    Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapy of obsessive compulsive disorder.
    Goodman WK; McDougle CJ; Price LH
    J Clin Psychiatry; 1992 Apr; 53 Suppl():29-37. PubMed ID: 1532962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.
    McDougle CJ; Price LH; Goodman WK; Charney DS; Heninger GR
    J Clin Psychopharmacol; 1991 Jun; 11(3):175-84. PubMed ID: 1820757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies.
    Flament MF; Bisserbe JC
    J Clin Psychiatry; 1997; 58 Suppl 12():18-22. PubMed ID: 9393392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment.
    Hollander E; DeCaria CM; Schneier FR; Schneier HA; Liebowitz MR; Klein DF
    J Clin Psychiatry; 1990 Mar; 51(3):119-23. PubMed ID: 2106515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
    Barr LC; Goodman WK; Anand A; McDougle CJ; Price LH
    Am J Psychiatry; 1997 Sep; 154(9):1293-5. PubMed ID: 9286191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.
    Chouinard G; Goodman W; Greist J; Jenike M; Rasmussen S; White K; Hackett E; Gaffney M; Bick PA
    Psychopharmacol Bull; 1990; 26(3):279-84. PubMed ID: 2274626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin reuptake inhibitors are the treatment of choice in obsessive compulsive disorder.
    Fineberg NA; Bullock T; Montgomery DB; Montgomery SA
    Int Clin Psychopharmacol; 1992 Jun; 7 Suppl 1():43-7. PubMed ID: 1517558
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacologic management of obsessive-compulsive disorder.
    Jackson CW; Morton WA; Lydiard RB
    South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of severe obsessive-compulsive disorder with fluvoxamine.
    Price LH; Goodman WK; Charney DS; Rasmussen SA; Heninger GR
    Am J Psychiatry; 1987 Aug; 144(8):1059-61. PubMed ID: 3111279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of depersonalization with serotonin reuptake blockers.
    Hollander E; Liebowitz MR; DeCaria C; Fairbanks J; Fallon B; Klein DF
    J Clin Psychopharmacol; 1990 Jun; 10(3):200-3. PubMed ID: 2115893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
    Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
    J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients.
    Jenike MA; Baer L; Summergrad P; Weilburg JB; Holland A; Seymour R
    Am J Psychiatry; 1989 Oct; 146(10):1328-30. PubMed ID: 2675643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.